Advertisement
Advertisement
U.S. markets open in 7 hours 37 minutes
Advertisement
Advertisement
Advertisement
Advertisement

NeuBase Therapeutics, Inc. (NBSE)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.8900-0.0400 (-1.02%)
At close: 4:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close3.9300
Open3.9600
Bid0.0000 x 900
Ask0.0000 x 1100
Day's Range3.7400 - 3.9700
52 Week Range3.2600 - 12.8900
Volume135,701
Avg. Volume148,675
Market Cap127.268M
Beta (5Y Monthly)-0.13
PE Ratio (TTM)N/A
EPS (TTM)-0.9220
Earnings DateDec 21, 2021 - Dec 28, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est16.25
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for NBSE

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • NeuBase Therapeutics, Inc.
    ANIP: Rating decreased to a SELLANI PHARMACEUTICALS INC has an Investment Rating of SELL; a target price of $39.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of Low.
    Rating
    Fair Value
    Economic Moat
    14 days agoArgus Research
View more
  • GlobeNewswire

    VBL Therapeutics Announces Appointment of Sam Backenroth as Chief Financial Officer and Establishes Operations in the United States

    Amos Ron to Retire as CFO and Will Continue to Serve as Corporate Secretary, Advisor to VBL Sam Backenroth, Chief Financial Officer, VBL Therapeutics Sam Backenroth, Chief Financial Officer, VBL Therapeutics TEL AVIV, Israel and NEW YORK, Oct. 05, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced the appointment of Sam Backenroth as chief financial officer (CFO) effective immediately. Mr. Backenroth is an accomplished corporate finance veteran with demonstrated success in

  • GlobeNewswire

    NeuBase to Participate at the Chardan 5th Annual Genetic Medicines Conference

    PITTSBURGH, Sept. 28, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, announced today that Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase, will participate in a fireside chat at the virtual Chardan 5th Annual Genetic Medicines Conference being held October 4 - 5. Chardan 5th Annual Genetic Medicines Conference

  • GlobeNewswire

    NeuBase to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

    PITTSBURGH, Sept. 15, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, announced today that Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase, will present a corporate overview at the virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit being held September 20 – 23. Oppenheimer Fall

Advertisement
Advertisement